Format

Send to

Choose Destination
JAMA Oncol. 2017 Jan 1;3(1):122-123. doi: 10.1001/jamaoncol.2016.2638.

Capecitabine and the Risk of Fingerprint Loss.

Author information

1
Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
2
Regional Criminal Investigations Division, National Police, The Hague, the Netherlands.
3
Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands3Apotheek Haagse Ziekenhuizen/HagaZiekenhuis, The Hague, the Netherlands.
PMID:
27560202
DOI:
10.1001/jamaoncol.2016.2638
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center